Safety and clinical efficacy of golimumab in the treatment of arthritides

Drug, Healthcare and Patient Safety

Volumn 2, Issue 1, 2010, Pages 169-180

  Simsek, Ismail ^a   Yazici, Yusuf ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Ankylosing spondylitis; Arthritis; Psoriatic arthritis; Rheumatoid

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GOLIMUMAB; HYDROXYCHLOROQUINE; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISONE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANEMIA; ANKYLOSING SPONDYLITIS; ANTIBODY TITER; AUTOIMMUNITY; CLINICAL ASSESSMENT; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; DEMYELINATING DISEASE; DISEASE ACTIVITY; DISEASE ACTIVITY SCORE; DISEASE DURATION; DISEASE SEVERITY; DISTRIBUTION VOLUME; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; ENTHESITIS; GASTROENTERITIS; HISTOPLASMOSIS; HUMAN; INFECTION; INJECTION SITE CONTUSION; INJECTION SITE ERYTHEMA; INJECTION SITE REACTION; INJECTION SITE WARMTH; JOINT SWELLING; LIVER HISTOPLASMOSIS; LOW DRUG DOSE; LYMPHOMA; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NAUSEA; NEUROPATHY; OPPORTUNISTIC INFECTION; OTITIS MEDIA; PANCYTOPENIA; PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PSORIASIS AREA AND SEVERITY INDEX; PSORIATIC ARTHRITIS; REMISSION; RESPIRATORY TRACT INFECTION; REVIEW; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SEPSIS; SIDE EFFECT; STEADY STATE; TUBERCULOSIS; TUBERCULOUS SPONDYLITIS; URINARY TRACT INFECTION;

EID: 78650711616     PISSN: None     EISSN: 11791365     Source Type: Journal    
DOI: 10.2147/DHPS.S6187     Document Type: Review

References (29)

1. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008;117(2):244-279.
2. Sokka T, Abelson B, Pincus T. Mortality in rheumatoid arthritis: 2008 update. Clin Exp Rheumatol. 2008;26(5 Suppl 51):S35-S61.
3. Gladman DD. Mortality in psoriatic arthritis. Clin Exp Rheumatol. 2008;26(5 Suppl 51):S62-S65.
4. Zochling J, Braun J. Mortality in ankylosing spondylitis. Clin Exp Rheumatol. 2008;26(5 Suppl 51):S80-S84.
5. Taylor PC, Feldmann M. Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis. Nat Rev Rheumatol. 2009;5(10):578-582.
6. Elewaut D, Matucci-Cerinic M. Treatment of ankylosing spondylitis and extra-articular manifestations in everyday rheumatology practice. Rheumatology (Oxford). 2009;48(9):1029-1035.
7. Fantuzzi F, Del Giglio M, Gisondi P, Girolomoni G. Targeting tumor necrosis factor alpha in psoriasis and psoriatic arthritis. Expert Opin Ther Targets. 2008;12(9):1085-1096.
8. Gomez-Reino JJ, Carmona L. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther. 2006;8(1):R29.
9. Hyrich KL, Lunt M, Watson KD, Symmons DP, Silman AJ. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum. 2007;56(1):13-20.
10. Zhou H, Jang H, Fleischmann RM, et al. Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis. J Clin Pharmacol. 2007;47(3):383-396.
11. Kay J, Matteson EL, Dasgupta B, et al. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum. 2008;58(4):964-975.
12. Kremer J, Ritchlin C, Mendelsohn A, et al. Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: fortyeight- week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2010;62(4):917-928.
13. Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum. 2009;60(4):976-986.
14. Inman RD, Davis JC Jr, Heijde D, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum. 2008;58(11):3402-3412.
15. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995;38(6):727-735.
16. Marra C. Rheumatoid arthritis: a primer for pharmacists. Am J Health Syst Pharm. 2006;63(18 Suppl 4):S4-S10.
17. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38(1):44-48.
18. Keystone EC, Genovese MC, Klareskog L, et al. Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD study. Ann Rheum Dis. 2009;68(6):789-796.
19. Emery P, Fleischmann RM, Moreland LW, et al. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebocontrolled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum. 2009;60(8):2272-2283.
20. Smolen JS, Kay J, Doyle MK, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet. 2009;374(9685):210-221.
21. Keystone E, Genovese MC, Klareskog L, et al. Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study. Ann Rheum Dis. 2010;69(6):1129-1135.
22. Fredriksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica. 1978;157(4):238-244.
23. Clegg DO, Reda DJ, Mejias E, et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum. 1996;39(12):2013-2020.
24. Rich P, Scher RK. Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis. J Am Acad Dermatol. 2003;49(2):206-212.
25. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27(4):361-368.
26. Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum. 2001;44(8):1876-1886.
27. Brandt J, Listing J, Sieper J, Rudwaleit M, van der Heijde D, Braun J. Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis. Ann Rheum Dis. 2004;63(11):1438-1444.
28. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis. 2004;38(9):1261-1265.
29. Yazici Y, Adler NM, Yazici H. Most tumour necrosis factor inhibitor trials in rheumatology are undeservedly called 'efficacy and safety' trials: a survey of power considerations. Rheumatology (Oxford). 2008;47(7):1054-1057.